<DOC>
	<DOCNO>NCT01796730</DOCNO>
	<brief_summary>This randomize , double-blind , 3-crossover trial 7-days washout baseline period follow three treatment period 21-days perform patient COPD . Patients randomize receive three treatment ( bambuterol 10mg , bambuterol 5 mg placebo ) .</brief_summary>
	<brief_title>Effects Safety Different Dose Bambuterol Chinese COPD Patients</brief_title>
	<detailed_description>Patients COPD meet inclusion criterion enter 7-days washout baseline period . After baseline period , patient randomly assign one follow treatment sequence : - Sequence I : bambuterol 10mg ( 21 day ) -washout ( 7 day ) - bambuterol 5mg ( 21 day ) - washout ( 7 day ) - placebo ( 21 day ) ; - Sequence II : bambuterol 5mg ( 21 day ) -washout ( 7 day ) - placebo ( 21 day ) - washout ( 7 day ) - bambuterol 10mg ( 21 day ) ; - Sequence III : placebo ( 21 day ) -washout ( 7 day ) - bambuterol 10mg ( 21 day ) - washout ( 7 day ) - bambuterol 5mg ( 21 day ) . During treatment period patient record adverse event use rescue medication ( Ipratropium bromide ) diary . At visit , pulmonary function test perform . At V2 , V4 V6 , force expiratory volume one second ( FEV1 ) force vital capacity ( FVC ) measure follow time : immediately tablet treatment , 0.5 , 1 , 2 , 3 , 4 , 6 , 9 , 12hrs administration tablet , FEV1 FVC area curve ( AUC ) 0~12 hour analyze . At V1 , V3 , V5 V7 , FVC measure time morning . Peak expiratory flow rate ( PEFR ) measure Mini-Wright peak flow meter morning treatment . All data evaluate safety status , monitor adverse event .</detailed_description>
	<mesh_term>Pulmonary Disease , Chronic Obstructive</mesh_term>
	<mesh_term>Bambuterol</mesh_term>
	<mesh_term>Terbutaline</mesh_term>
	<criteria>COPD , disease stable phase Giving write informed consent Age 40 80 year ( inclusive ) Chinese ethnicity 30 % predicate normal ≤Post bronchodilator FEV1 ≤ 70 % predicate normal Post bronchodilator FEV1/FVC ≤ 70 % ( Note : post bronchodilator FEV1 test 2030 minute Salbutamol use ( inhaled via meter dose inhaler ( MDI ) spacer ) . COPD acute exacerbation 4 week prior enrollment Patients history asthma , allergic rhinitis , atopy Use disallow drug Clinically relevant abnormal laboratory value suggest undiagnosed disease require clinical evaluation ( assessed Investigator ) Severe psychiatric neurological disorder Congestive heart failure severity grade IV accord New York Heart Association ( NYHA ) Haemodynamically significant cardiac arrhythmias heart valve deformation CT Xray finding indicate acute pulmonary disease COPD ( e.g . tuberculosis , severe bronchiectasis , tumor ) Severe immunological disease ( e.g . HIV infection , multiple sclerosis , lupus erythematosus , progressive multifocal leukoencephalopathy ) Severe acute infectious disease ( e.g . tuberculosis acute hepatitis ) Any diagnosis malignant disease ( except basal cell carcinoma ) within 5 year trial start Alcohol drug abuse within past year Suspected hypersensitivity Bambuterol ingredients thereof , contraindication use thereof Pregnancy , breast feeding , plan oocyte donation oocyte implantation Participation another trial ( use investigational product ) within 30 day precede baseline visit V1 reentry patient previously enrol trial Suffering concomitant disease might interfere trial procedure evaluation</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>March 2015</verification_date>
	<keyword>efficacy</keyword>
	<keyword>safety</keyword>
	<keyword>Bambuterol tablet</keyword>
	<keyword>COPD</keyword>
</DOC>